Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$23.53
▼ $0.18 (-0.8%)
Market data updated: 09/17 07:35 AM
Fundamentals updated: 09/17/2026
News analyzed: 09/17/2026
Market Cap
$12.16B
Day Range
$23.18 - $23.87
52-Week Range
$15.73 - $30.00
Beta
—
Next Earnings
28.10.2026
BAX is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-0.4% (1Y)
Strengths: 4/30 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Liquidity risk
Current ratio: 2.31
Risk
Biggest negative driver
Operating margin
Operating margin: -2.7% (negative)
Fundamental
What to watch next
When today echoes the past.
74/100
Similarity
15
Historical Matches
87/100
Analog Quality
-7.1%
Median 40D Outcome
60/100
Pattern Consistency
🟢 Bullish
47%
+1.7% … +8.4%
🟡 Base
13%
+0.3% … +0.7%
🔴 Bearish
40%
-11.3% … -10.2%
Typical timeframe (based on real historical rates clearing a 60% bar): 5 trading days.
📌 Bottom line: Out of 15 similar historical cases for this stock, 47% (95% CI 25%–70%) saw the stock rise within 20 trading days, with a median gain of +0.9%.
Echo #1 — Momentum Breakout
7 occurrence(s) · 57% historical success
Historical outcome rate is not a probability — it's what happened in this specific historical sample, with a 95% confidence range.
| Horizon | Positive rate (95% CI) | Median | 25th–75th pct | Baseline median |
|---|---|---|---|---|
| 5D | 73% (48%–89%) | +3.1% | +1.1% … +3.4% | +0.2% |
| 10D | 60% (36%–80%) | +1.9% | -2.3% … +2.6% | +0.2% |
| 20D | 47% (25%–70%) | +0.9% | -10.2% … +2.9% | -0.2% |
| 40D | 33% (15%–58%) | -7.1% | -10.8% … +3.8% | -0.8% |
| 60D | 33% (15%–58%) | -6.6% | -16.1% … +1.6% | -1.3% |
Sample size: 15 analogs, each at least 10 trading days apart (no double-counted overlapping events).
What happened after each historical match (20-day return)
| Date | Similarity | Regime | 20D outcome | 60D outcome |
|---|---|---|---|---|
| 2025-03-25 | 74/100 | ✓ Consolidation | -10.1% | -9.0% |
| 2024-10-07 | 72/100 | Downtrend | +0.1% | -18.2% |
| 2022-06-23 | 71/100 | Downtrend | +1.7% | -10.2% |
| 2021-02-01 | 71/100 | Downtrend | +1.7% | +13.9% |
| 2018-10-12 | 70/100 | ✓ Consolidation | -10.9% | -5.5% |
| 2025-07-17 | 70/100 | Downtrend | -12.3% | -21.3% |
| 2020-11-04 | 69/100 | Downtrend | +0.9% | +1.1% |
| 2022-12-16 | 69/100 | Downtrend | -11.5% | -22.8% |
| 2018-02-13 | 68/100 | ✓ Consolidation | +4.1% | +9.2% |
| 2023-08-04 | 67/100 | Consolidation | -7.6% | -27.0% |
| 2022-04-28 | 67/100 | Downtrend | +7.0% | -5.7% |
| 2022-03-14 | 67/100 | Downtrend | +1.0% | -6.6% |
| 2021-08-10 | 67/100 | Downtrend | +12.1% | +8.4% |
| 2023-05-31 | 66/100 | Downtrend | +9.8% | +2.0% |
| 2024-04-17 | 65/100 | ✓ Consolidation | -10.3% | -14.0% |
Every accepted match is compared to today across 6 domains (price structure, momentum, technical, volatility, volume, relative strength) using z-scored feature distances — no single indicator dominates. Matches within 10 trading days of each other count as one event, not independent evidence. Outcome rates use a Wilson confidence interval (never a raw percentage alone), the mean return is winsorized against extreme outliers, and "Analog Quality" separately captures sample size, data completeness, and regime match — distinct from raw similarity. Relative strength is measured against SPY and against XLV (this stock's sector).
Cross-stock analogs — real other companies, not this stock's own history.
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
41
Today
45
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
25d ago · $26.34
Evidence: 6 bullish / 4 bearish technical signals agreeing
What happened after
28d ago · $26.64
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
28d ago · $26.64
Evidence: 5 bullish / 5 bearish technical signals agreeing
What happened after
29d ago · $25.87
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
29d ago · $25.87
Evidence: 4 bullish / 8 bearish technical signals agreeing
What happened after
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🕰️ StockIQ Time Machine
What did StockIQ know — and when? Pick a date from the real accumulated history.
As of August 18, 2026
Then
45
$25.78
Now
41
$23.53
What happened since
Signals detected by this date
No signals detected by this date
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
40
Quality
42
Value
50
Momentum
33
Risk
42
Sentiment
86
Fundamental
23
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
SCANNING BAX...
Recent media coverage of Baxter International highlights its **revised 2026 financial outlook**, raised due to strong Q2 growth despite challenges like rising manufacturing costs, tariffs, and pricing pressures. The company also appears in broader market reports on **drug reconstitution systems**, a growing sector (projected to reach $10.8 billion by 2035) where Baxter is a key player alongside competitors like ICU Medical and B. Braun. No other company-specific developments are prominently featured in the provided sources.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Baxter International. News trend score: 86. Reason: 7 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
26
🎯 Conviction (vs. Emotion)
36
Psychology
28
Fundamentals
23
Technical
33
Valuation
50
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+22%
Market Narrative
49
Fundamental Reality
36
Narrative Gap
+13
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The dominant **herding** state (78) reflects BAX’s synchronized decline with peers, suggesting traders are following broader sector trends rather than independent analysis. The **euphoria** score (28) hints at lingering optimism despite weak momentum, while the **narrative gap** (13-point discrepancy) implies traders may be overestimating fundamentals relative to technicals. The absence of panic or FOMO signals—despite negative sentiment—points to cautious, not frantic, behavior. The key question is whether this herd alignment persists or if divergence emerges as external catalysts surface.
Updated: 09/09/2026, 01:42 AM
What could change this?
👥 What the crowd believes
"BAX raises its 2026 sales and earnings outlook after strong Q2 growth"
"global drug reconstitution systems market projected to increase from USD 5.9B to USD 10.8B by 2035"
📈 11D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 97/100
🔴 Weakest match
Morgan Housel — 9/100
🗣️ Why do they disagree?
The methodologies here split sharply between those who see potential in BAX’s technical or cyclical positioning and those that flag fundamental, valuation, or structural risks. Samuel Armstrong Nelson’s high score suggests the stock’s cycle may be near an oversold trough, aligning with a contrarian or momentum-driven view, while Charles Mackay’s moderate score hints at growing speculative interest—both leaning cautiously optimistic. In contrast, the majority of the models—especially those from Graham, Livermore, and Marks—warn against the stock due to weak valuation, trend resistance, or late-cycle risks, with Graham’s Enterprising Investor variant and Schwager’s disciplined approach outright dismissing it. Meanwhile, Fisher, Lynch, and Housel’s near-zero scores reflect a consensus that BAX lacks the growth, quality, or patience-friendly stability they prioritize, while Veblen’s low score implies it may be a speculative play without meaningful long-term substance.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 97
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 66
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 62
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 48
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 47
Mixed — doesn't clearly pass Graham's tests
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 46
Some discount, but not the deep 'net-net' bargain Graham's enterprising bar sets
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 44
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 42
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 41
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 39
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟡 37
Liquidity position Bagehot would flag as a real risk
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 32
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 21
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 17
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 12
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 9
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Based on the last 300 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (2 bullish · 8 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
30.1%
Operating Margin
-2.7%
Net Margin
-8.5%
EBITDA Margin
6.0%
ROE
-15.6%
ROA
-4.8%
ROIC
—
EPS
-$1.87
Cash
$1.97B
Total Debt
$9.44B
Current Ratio
2.31
Debt/Equity
1.54
אין נתונים היסטוריים זמינים.
Total dividend per share paid each year, over the last 5 years.
| Ex-Dividend Date | Amount per Share |
|---|---|
| 28.8.2026 | $0.010 |
| 29.5.2026 | $0.010 |
| 28.5.2026 | $0.010 |
| 27.2.2026 | $0.010 |
| 26.2.2026 | $0.010 |
| 28.11.2025 | $0.010 |
| 27.11.2025 | $0.010 |
| 29.8.2025 | $0.170 |
| 28.8.2025 | $0.170 |
| 30.5.2025 | $0.170 |
| 29.5.2025 | $0.170 |
| 28.2.2025 | $0.170 |
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$11.95
Tangible Book Value per Share (Tangible NAV)
-$6.18
Sentiment based on basic keywords (not AI) — 7 positive, 12 neutral, 1 negative out of the last 20 articles.
Yahoo · 16.9.2026
SeekingAlpha · 9.9.2026
Benzinga · 8.9.2026
Zacks · 7.9.2026
Yahoo · 7.9.2026
Yahoo · 7.9.2026
GlobeNewswire · 7.9.2026
StockStory · 3.9.2026
Yahoo · 3.9.2026
Yahoo · 1.9.2026
StockStory · 1.9.2026
Yahoo · 30.8.2026
Yahoo · 26.8.2026
Simply Wall St. · 26.8.2026
SeekingAlpha · 24.8.2026
Yahoo · 21.8.2026
StockStory · 21.8.2026
Yahoo · 20.8.2026
CFO Dive · 20.8.2026
Yahoo · 20.8.2026
Baxter International (BAX) currently has a StockIQ AI score of 41/100, rated "Weak". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
BAX currently scores 41/100 (Weak) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
BAX's technical score is 33/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Current ratio: 2.31; Price is above the 200-day average; +13.4% over the last 3 months relative to the index.
Based on the real signals StockIQ computed: Operating margin: -2.7% (negative); Net margin: -8.5% (negative); Operating margin is eroding over time.
Yes — BAX has a real recorded dividend payment history on StockIQ. See the Dividends section on this page for the actual per-share amounts and dates.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Hider Andrew P. | Tax Withholding in Shares | 2.9.2026 | 54,276 | -54,276 | $25.70 |
| Foster Julie | Tax Withholding in Shares | 2.9.2026 | 2,098 | -2,098 | $25.70 |
| Teaff James | Tax Withholding in Shares | 1.9.2026 | 750 | -750 | $25.48 |
| Wallace Steven P. | Tax Withholding in Shares | 2.6.2026 | 153 | -153 | $18.68 |
| Teaff James | Tax Withholding in Shares | 2.6.2026 | 321 | -321 | $18.68 |
| Teaff James | Tax Withholding in Shares | 2.6.2026 | 31,063 | -321 | $18.68 |
| Wallace Steven P. | Tax Withholding in Shares | 2.6.2026 | 70,128 | -153 | $18.68 |
| Zielinski Anita A | Grant/Award from Employer | 1.6.2026 | 13,426 | +13,426 | — |
| Zielinski Anita A | Grant/Award from Employer | 1.6.2026 | 59,714 | +13,426 | — |
| Craig Jeffrey A | Grant/Award from Employer | 5.5.2026 | 12,836 | +12,836 | — |
| Ampofo William A. II | Grant/Award from Employer | 5.5.2026 | 12,836 | +12,836 | — |
| SCHLICHTING NANCY M | Grant/Award from Employer | 5.5.2026 | 12,836 | +12,836 | — |
| McDonnell Michael R. | Grant/Award from Employer | 5.5.2026 | 12,836 | +12,836 | — |
| Wendell Amy McBride | Grant/Award from Employer | 5.5.2026 | 12,836 | +12,836 | — |
| MORRISON PATRICIA | Grant/Award from Employer | 5.5.2026 | 12,836 | +12,836 | — |
| Shafer David Brent | Grant/Award from Employer | 5.5.2026 | 12,836 | +12,836 | — |
| Wilkes David S. | Grant/Award from Employer | 5.5.2026 | 12,836 | +12,836 | — |
| MORRISON PATRICIA | Grant/Award from Employer | 5.5.2026 | 42,386 | +12,836 | — |
| SCHLICHTING NANCY M | Grant/Award from Employer | 5.5.2026 | 34,994 | +12,836 | — |
| Ampofo William A. II | Grant/Award from Employer | 5.5.2026 | 30,375 | +12,836 | — |
| Craig Jeffrey A | Grant/Award from Employer | 5.5.2026 | 23,662 | +12,836 | — |
| McDonnell Michael R. | Grant/Award from Employer | 5.5.2026 | 14,647 | +12,836 | — |
| Shafer David Brent | Grant/Award from Employer | 5.5.2026 | 72,804 | +12,836 | — |
| Wendell Amy McBride | Grant/Award from Employer | 5.5.2026 | 44,235 | +12,836 | — |
| Wilkes David S. | Grant/Award from Employer | 5.5.2026 | 37,076 | +12,836 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
23,293,667 shares short as of 2026-08-31 · vs. 32,667,256 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
47.2% of trading volume this week was short selling, vs. 59.0% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology